NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
Country Total |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 12953 | 4.9% | 3741 | 1.4% | 561 | 0.2% | 31 | 0.0% | 57 | 0.0% | 394 | 0.1% | 248563 | 93.3% | 266300 | 100.0% |
ASCUS | 8635 | 27.5% | 6346 | 20.2% | 2341 | 7.5% | 58 | 0.2% | 45 | 0.1% | 481 | 1.5% | 13454 | 42.9% | 31360 | 100.0% |
LSIL | 3958 | 21.7% | 5839 | 32.0% | 2671 | 14.7% | 21 | 0.1% | 13 | 0.1% | 296 | 1.6% | 5430 | 29.8% | 18228 | 100.0% |
Atypical glandular cells/AGC | 355 | 36.0% | 132 | 13.4% | 109 | 11.1% | 96 | 9.7% | 49 | 5.0% | 25 | 2.5% | 220 | 22.3% | 986 | 100.0% |
Unclear atypia | 125 | 31.6% | 59 | 14.9% | 82 | 20.7% | 9 | 2.3% | 13 | 3.3% | 15 | 3.8% | 93 | 23.5% | 396 | 100.0% |
ASC-H | 540 | 16.3% | 699 | 21.0% | 1768 | 53.2% | 36 | 1.1% | 44 | 1.3% | 26 | 0.8% | 209 | 6.3% | 3322 | 100.0% |
HSIL | 311 | 6.0% | 491 | 9.5% | 3764 | 72.8% | 89 | 1.7% | 149 | 2.9% | 38 | 0.7% | 331 | 6.4% | 5173 | 100.0% |
Suspected Adenocarcinom | 15 | 6.7% | 5 | 2.2% | 7 | 3.1% | 61 | 27.4% | 58 | 26.0% | 3 | 1.3% | 74 | 33.2% | 223 | 100.0% |
Adenocarcinoma | 1 | 9.1% | . | . | . | . | . | . | 3 | 27.3% | . | . | 7 | 63.6% | 11 | 100.0% |
Malignant tumor with unclear origin | 1 | 2.9% | 1 | 2.9% | 3 | 8.6% | . | . | 15 | 42.9% | 2 | 5.7% | 13 | 37.1% | 35 | 100.0% |
Squamous cell cancer | 1 | 0.9% | 2 | 1.8% | 30 | 27.0% | . | . | 58 | 52.3% | 2 | 1.8% | 18 | 16.2% | 111 | 100.0% |
Totalt | 26895 | 8.2% | 17315 | 5.3% | 11336 | 3.5% | 401 | 0.1% | 504 | 0.2% | 1282 | 0.4% | 268412 | 82.3% | 326145 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M69760, M80001, M80009, M80109, M80203, M80413, M80503, M80703, M80706, M81403, M81406, M81407, M81409, M82003, M82603, M83803, M83806, M84006, M84413, M84423, M84603, M84613, M84616, M85603, M89303, M89313, M89803, M96803, M98233 |